Valuation : Colinz Laboratories Limited

Market Cap 183M 1.94M 1.67M 1.57M 1.43M 2.68M 2.69M 18.52M 7.19M 93.78M 7.27M 7.11M 302M P/E 2025
36.8x
P/E 2026 21.8x
Enterprise Value 101M 1.07M 924K 869K 794K 1.49M 1.49M 10.27M 3.99M 52.02M 4.03M 3.94M 168M EV / Sales 2025
2.04x
EV / Sales 2026 0.5x
Free-Float
31.44%
Yield 2025 *
-
Yield 2026 -
07-30 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
06-17 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
05-25 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
04-29 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
01-24 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-16 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
11-27 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
11-08 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
11-03 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/07/25 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/05/25 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
16/05/25 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
1 day+1.48%
1 week-1.95%
Current month+1.24%
1 month-11.19%
3 months+17.70%
6 months+64.87%
Current year+35.30%
1 week 69.25
Extreme 69.25
74.99
1 month 68.89
Extreme 68.89
85.99
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 15.7
Extreme 15.7
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 19/05/2019
Compliance Officer - 30/11/2025
Director TitleAgeSince
Director/Board Member 74 25/11/1990
Director/Board Member 33 07/08/2024
Director/Board Member 76 07/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+1.48%-1.95%+68.74%+73.88% 1.94M
-0.89%-1.09%+19.16%+67.77% 48.26B
-1.72%-1.15%+45.80%+117.34% 40.5B
-0.70%-2.70%-10.84%+11.79% 11.85B
-2.01%-5.96%+10.47%+76.64% 11.83B
+2.31%0.00%+26.67%+153.33% 9.36B
+0.08%-4.11%+24.83%+43.80% 7.5B
-1.67%-0.35%+41.04%-11.59% 7.37B
-0.89%-3.09%+18.78%+207.82% 7.28B
-0.16%-2.36%-46.14%+16.28% 5.19B
Average -0.42%-2.08%+19.85%+75.71% 14.91B
Weighted average by Cap. -0.95%-1.71%+22.87%+82.78%

Financials

2025 2026
Net sales 65.28M 691K 595K 560K 511K 957K 959K 6.61M 2.57M 33.49M 2.6M 2.54M 108M 61.36M 650K 559K 526K 481K 899K 902K 6.22M 2.41M 31.48M 2.44M 2.39M 101M
Net income 4.97M 52.6K 45.26K 42.58K 38.9K 72.77K 72.97K 503K 195K 2.55M 198K 193K 8.21M 5.14M 54.49K 46.89K 44.12K 40.3K 75.39K 75.6K 521K 202K 2.64M 205K 200K 8.5M
Net Debt -49.09M -520K -447K -421K -385K -719K -721K -4.97M -1.93M -25.19M -1.95M -1.91M -81.14M -81.39M -862K -742K -698K -638K -1.19M -1.2M -8.25M -3.2M -41.76M -3.24M -3.17M -135M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
62
Date Price Change Volume
04/09/26 ₹72.56 +1.48% 47
03/09/26 ₹71.50 +2.72% 351
02/09/26 ₹69.61 -4.38% 2,216
01/09/26 ₹72.80 +1.58% 10
31/08/26 ₹71.67 -3.15% 1,448
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock